Peripheral nerve injury-caused hyperexcitability and abnormal ectopic discharges in the primary sensory neurons of dorsal root ganglion (DRG) play a key role in neuropathic pain development and maintenance. The two-pore domain background potassium (K 2P ) channels have been identified as key determinants of the resting membrane potential and neuronal excitability. However, whether K 2P channels contribute to neuropathic pain is still elusive. We reported here that K 2P 1.1, the first identified mammalian K 2P channel, was highly expressed in mouse DRG and distributed in small-, medium-, and large-sized DRG neurons. Unilateral lumbar (L) 4 spinal nerve ligation led to a significant and time-dependent reduction of K 2P 1.1 mRNA and protein in the ipsilateral L4 DRG, but not in the contralateral L4 or ipsilateral L3 DRG. Rescuing this reduction through microinjection of adeno-associated virus-DJ expressing full-length K 2P 1.1 mRNA into the ipsilateral L4 DRG blocked spinal nerve ligation-induced mechanical, thermal, and cold pain hypersensitivities during the development and maintenance periods. This DRG viral microinjection did not affect acute pain and locomotor function. Our findings suggest that K 2P 1.1 participates in neuropathic pain development and maintenance and may be a potential target in the management of this disorder.
Introduction
Peripheral nerve injury-induced neuropathic pain is one of major clinical disorders characterized by spontaneous ongoing or intermittent burning pain, sensory abnormalities (dysesthesia), an increased response to painful stimuli (hyperalgesia), and pain in response to normally innocuous stimuli (allodynia). 1 Treatment options of this disorder are limited in part due to our incomplete understanding of the mechanisms that underlie the induction and maintenance of neuropathic pain. One of the primary causes of neuropathic pain is hypersensitivities and abnormal ectopic discharges that arise in the neuromas at the site of peripheral nerve injury and the primary sensory neurons of dorsal root ganglion (DRG). [1] [2] [3] [4] Exploring how peripheral nerve injury leads to these abnormal neuronal activities in the DRG may provide a potential new avenue for the prevention and treatment of neuropathic pain.
The two-pore domain background potassium (K 2P ) channel family and the leak currents carried by K 2P channels have been identified as key determinants of neuronal activity throughout the nervous system. 5 In mammalians, 15 subunits have been identified and were further divided into six subfamilies based on their structural and functional properties including TWIK, TREK, TASK, THIK, TRESK, and TALK. 5, 6 K 2P channels control neuronal excitability by setting the resting membrane potential and input resistance. 7, 8 Their expression and function could also be modulated by multiple neurotransmitters and modulators.
9,10 K 2P 1.1, also known as TWIK1, was the first identified K 2P channel and was found to be opened at rest and therefore is capable of driving the membrane potential towards the equilibrium potential for K þ . 9,11 K 2P 1.1 mRNA is highly expressed in mouse DRG and mainly distributed in large and medium DRG neurons. 12 Peripheral spared nerve lesion produces a significant downregulation of K 2P 1.1 mRNA in the injured DRG 1, 2, and 4 weeks after lesion. 12 However, whether this downregulation occurs at the development (or the early) period of neuropathic pain is still elusive. More importantly, whether nerve injuryinduced DRG K 2P 1.1 downregulation contributes to the development and maintenance of neuropathic pain is unknown.
In the present study, we first characterized the subpopulation distribution patterns and neurochemical properties of K 2P 1.1-positive cells. Second, we examined the time-dependent change of K 2P 1.1 mRNA and protein in the injured mouse DRG after unilateral lumbar (L) 4 spinal nerve ligation (SNL). Finally, we tested whether rescuing K 2P 1.1 downregulation by overexpressing fulllength K 2P 1.1 gene in the injured DRG affected pain hypersensitivities during the development and maintenance periods of SNL-induced neuropathic pain.
Materials and methods

Animal preparations
Eight-week-old male CD1 mice (Charles River Lab., Wilmington, MA) were used in this experiment. They were housed in a temperature-controlled room with a standard 12-h light-dark cycle and had free access to food and water. Mice were habituated to the testing environment daily for three days before behavioral testing. They were randomly assigned into different experimental or control groups. The group sizes were based on previous experience. All procedures used were approved by the Animal Care and Use Committee at the Rutgers New Jersey Medical School and consistent with the ethical guidelines of the US National Institutes of Health and the International Association for the Study of Pain. All of the experimenters were blind to treatment condition.
DRG microinjection
DRG microinjection was carried out as described previously. 9, [13] [14] [15] [16] [17] [18] Briefly, a dorsal midline incision was made in the lower lumbar region. The left L 3/4 articular processes were exposed and then removed with small rongeurs. After the DRG was exposed, the viral solution (1 ml, 2 Â 10 10 ) was injected into the left L 4 DRG with a glass micropipette connected to a Hamilton syringe. The pipette was removed 10 min after injection. The surgical field was irrigated with sterile saline and the skin incision closed with wound clips.
SNL-induced neuropathic pain model
A mouse neuropathic pain model of unilateral L 4 SNL was carried out as described previously. 15, 16, 19 Briefly, animals were anesthetized with 2-3% isoflurane. The left fifth lumbar transverse process was identified and then was separated from its muscle attachments. The underlying fourth spinal nerve was carefully isolated and tightly ligated with a 7-0 silk suture under a surgical microscope. The ligated nerve was then transected just distal to the ligature. The skin and muscles were closed in layers. The surgical procedure for the sham group was identical to that of the SNL group, except that the spinal nerve was not transected or ligated.
Behavioral tests
Mechanical behavioral test was carried out as described previously. 15, 16 Briefly, mice were placed in a plastic chamber over a metal mesh floor. After 30-min habituation, two calibrated von Frey filaments (0.07 and 0.4 g; Stoelting Co., Wool Dale, IL) were applied to the plantar surface of the hind paw for approximately 1 s, and each stimulation was repeated 10 times to both hind paws. The occurrence of paw withdrawal in each of these 10 trials was expressed as a percent response frequency. This percentage will be used as an indication of the amount of paw withdrawal.
Thermal behavioral test was performed as described previously. 15, 16 In brief, each mouse was placed in a plastic chamber above a glass plate. After 30-min habituation, a radiant heat from Model 336 Analgesic Meter (IITC Life Science, Instruments, Woodland Hills, CA) was applied by aiming a beam of light through a hole in the light box through the glass plate to the middle of the plantar surface of each hind paw. When the animal lifts its paw in response to the heat, the light beam was turned off. The time from the start of light beam to the foot lift was defined as paw withdrawal latency. Five minutes was allowed between stimulations and five measurements were averaged for each side. A cut-off time of 20 s was used to prevent tissue damage.
Cold behavioral test was carried out as previously described. 15, 16 Each mouse was placed in a Plexiglas chamber on the cold aluminum plate, the temperature of which was set at 0 C and monitored continuously by a thermometer. The length of time between the placement of the hind paw on the plate and the animal jumping, with or without paw licking and flinching, was defined as the paw withdrawal latency. Ten minutes was allowed between three repeated trials. A cut-off time of 20 s was used to avoid paw tissue damage.
Locomotor function was carried out on day 7 post-SNL or sham surgery. Three reflexes were observed. (1) Placing reflex: The mouse's hind limbs were hold slightly lower than the fore limbs, and the dorsal surfaces of the hind paws were brought into contact with the edge of a table. Whether the hind paws were placed on the table surface reflexively was recorded. (2) Grasping reflex: The mouse was placed on a wire grid and the experimenter recorded whether the hind paws grasped the wire on contact. And (3) Righting reflex: The mouse was placed on its back on a flat surface and whether it immediately assumed the normal upright position was recorded. Five trials were conducted for each test and scores were derived from counts of normal reflexes for each trial. General behavior, including spontaneous activity, was assessed.
Plasmid construction and virus production
To construct the plasmid expressing full-length K 2P 1.1 mRNA, total RNA from mouse DRG tissue was extracted by the Trizol method (Invitrogen/Thermo Fisher Scientific, Grand Island, NY), treated with DNase I (New England Biolabs, Ipswich, MA), and reverse-transcribed using the gene-specific primer 5'-ATTGGAATGCAAACCCAGAG-3'. Then the fulllength sequence of K 2P 1.1 cDNA was amplified using the following primers (Forward: 5'-ATAGAATTCGC CACCATGCTGCAGTCCCTGG-3'; Reverse: 5'-GTA GGATCCTCAGTGGTCTGCAGAGCCAT-3').
The K 2P 1.1 cDNA was inserted into the pro-viral plasmid (pAAV-MCS) by the EcoRI and BamHI restriction sites. The cDNA sequence and recombinant clone were verified by using DNA sequencing.
The adeno-associated virus (AAV)-DJ viral particles carrying the cDNA were prepared using AAV-DJ Helper Free Packaging System (Cell Biolabs, Inc., San Diego, CA). Briefly, HEK293-AAV cells were transfected with a pAAV-MCS that expressed K 2P 1.1 or enhanced green fluorescent protein (EGFP), pAAV-DJ-RC, and pHelper using a PEI Transfection method. Three days later, the transfected cells were collected and suspended in serum-free DMEM. After four freeze-thaw cycles, the AAV supernatant was collected by centrifugation at 10,000 g for 10 min and concentrated using AAV Purification Standard Kit (Cell Biolabs, Inc.).
Quantitative real-time reverse transcription-polymerase chain reaction
Total RNA extraction and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) were performed according to our previously published protocols. [13] [14] [15] [16] 18 Briefly, mice were sacrificed under isoflurane anesthesia, and bilateral L 4 DRGs was rapidly collected. To obtain enough RNA, L 4 DRGs from four mice per time point were pooled. Total RNA was extracted by using the miRNeasy kit with on-column digestion of genomic DNA according to manufacturer's instructions (QIAGEN, Valencia, CA), treated with an overdose of DNase I (New England Biolabs, Ipswich, MA), and reversed-transcribed with the ThermoScript reverse transcriptase (Invitrogen/ThermoFisher Scientific) and oligo (dT) primers (Invitrogen/ThermoFisher Scientific). Template (4 ml) was amplified in a BIO-RAD CFX96 real-time PCR system (Bio-Rad Laboratories, Hercules, CA) by using the following primers (K 2P 1.1: 5'-CAACGCCTCGGGAAATTGGA-3' (forward) and 5'-CCCCAGCGTATGTGGAAGTAG-3' (reverse). Tuba1a: 5'-GTGCATCTCCATCCATGTTG (forward) and 5'-GTGGGTTCCAGGTCTACGAA-3' (reverse)). Each sample was run in triplicate in a 20 ml reaction with 250 nM forward and reverse primers, 10 ml of Advanced Universal SYBR Green Supermix (Bio-Rad Laboratories), and 20 ng of cDNA. The PCR amplification consisted of an initial 3 min at 95 C followed by 40 cycles of 95 C for 10 s, 60 C for 30 s, and 72 C for 30 s. Ratios of ipsilateral side mRNA levels to contralateral side mRNA levels were calculated by using the ÁCt method (2 ÀÁÁCt ) at a threshold of 0.02. All data were normalized to Tuba1a mRNA, which has been demonstrated to be stable even after peripheral nerve injury insult in mice. [14] [15] [16] Western blot analysis
The detailed protocol for Western blot analysis was described previously. 14, 18 In brief, mice were sacrificed under isoflurane anesthesia and ipsilateral L 4 or L 3/4 DRGs were collected and rapidly frozen in liquid nitrogen. The tissues were homogenized in chilled lysis buffer (10 mM Tris, 5 mM MgCl 2 , 5 mM EGTA, 250 mM sucrose, 1 mM phenylmethylsulfonyl fluoride, 1 mM DTT, and 40 mM leupeptin). After centrifugalized at 4 C for 15 min at 1000 g, the supernatant was collected. After protein concentration was measured, the samples were heated at 99 C for 5 min and loaded onto a 4%-20% precast polyacrylamide gel (Bio-Rad Laboratories). The proteins were then electrophoretically transferred onto 0.2 mm pore-size nitrocellulose membranes (BioRad Laboratories). The membranes were blocked with 3% nonfat milk in Tris-buffered saline containing 0.1% Tween-20 for 1 h and then incubated with primary rabbit anti-K 2P 1.1 (1:1000; Alomone Labs, Jerusalem, Israel) or rabbit anti-GAPDH (1:1000; Santa Cruz Biotechnology, Dallas, TX) at 4 C overnight under gentle agitation. After being incubated with horseradish peroxidaseconjugated anti-rabbit secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA), the blots were developed with chemiluminescent regents (Clarity Western ECL Substrate; Bio-Rad Laboratories). The image signals were visualized by using ChemiDoc XRS þ System (Bio-Rad Laboratories). The intensity of blots was quantified with Image Lab software (Bio-Rad Laboratories). The bands of K 2P 1.1 at the different time points were normalized to the corresponding bands of GAPDH.
Immunohistochemistry
After being deeply anesthetized with isoflurane, the mice were perfused through the left ventricle with 20 mL of 0.01 M phosphate-buffered saline (PBS, pH 7.4) followed by 100 mL of 4% paraformaldehyde in 0.01 M phosphate buffer (pH 7.4). Bilateral L 4 DRGs were removed, post-fixed in the same fixative at 4 C overnight, and dehydrated in 30% sucrose in 0.01 M PBS overnight at 4 C. The DRG was sectioned at the thickness of 20 mm.
For the single labeling, every fourth section was collected (at least 3-4 sections/DRG). Single-label immunofluorescence histochemistry was carried out as described previously. 20, 21 After being blocked for 1 h at 37 C in PBS containing 10% goat serum and 0.3% TritonX-100, the sections were incubated alone with primary rabbit anti-K 2P 1.1 (1:1000, Alomone Labs) over two nights at 4 C. The sections were then washed with PBS and incubated with goat anti-rabbit IgG conjugated with Cy2 (1:300, Jackson ImmunoResearch Laboratories) for 2 h at room temperature. Control experiments included substitution of normal rabbit serum for the primary antiserum and omission of the primary antiserum. Finally, the sections were rinsed in 0.01 M PBS and mounted onto gelatin-coated glass slides. Cover slips were applied with a mixture of 50% glycerin and 2.5% triethylene diamine in 0.01 M PBS. All immunofluorescence-labeled images were examined under a Nikon TE2000E fluorescence microscope (Nikon Co., Japan) and randomly captured with a CCD spot camera (1-3 fields/section). All labeled and unlabeled neurons with nuclei were counted. Cell profiles were outlined, and cell area was calculated by using the imaging software Image-Pro Plus (Media Cybernetics, Silver Spring, MD).
For the double labeling, two sets of sections (at least 2-3 sections/set) were collected from each tissue by grouping every sixth serial section. Double-label immunofluorescence histochemistry was carried out as described previously. 20, 21 The sections were incubated overnight at 4 C with primary rabbit anti-K 2P 1.1 (1:1000, Alomone Labs) plus one of following primary antibody: chicken anti-bIII-tubulin (1:300, Millipore), mouse anti-Glutamine synthetase (1:500, Millipore), mouse anti-NF200 (1:1000, Sigma), biotinylated IB4 (1:300, Sigma), and mouse anti-CGRP (1:500, Abcam). The sections were then incubated for 2 h at room temperature with a mixture of goat anti-rabbit IgG conjugated with Cy2 (1:
Statistical analysis
All of the results are given as means AE SEM. The data were statistically analyzed with two-tailed, paired Student's t-test and a one-way or two-way analysis of variance (ANOVA). When ANOVA showed a significant difference, pairwise comparisons between means were tested by the post hoc Turkey method (SigmaPlot 12.5, San Jose, CA). Significance was set at P < 0.05.
Results
Distribution of K 2P 1.1-positive immunoreactivity in DRG
We first examined the distribution pattern of K 2P 1.1 in the mouse DRG. Using double labeling for K 2P 1.1 and bIII-tubulin (a specific neuronal marker) or glutamine synthetase (GS, a marker for satellite glial cells), we found that K 2P 1.1 co-expressed with bIII-tubulin (Figure 1(a) ), but not with GS (Figure 1(b) ), indicating that K 2P 1.1 is expressed exclusively in the neurons of DRG. Approximately 89.4% (1184/1324) of DRG neurons were positive for K 2P 1.1 (Figure 2(a)) . A cross-sectional area analysis of neuronal somata found that approximately 24.3% of K 2P 1.1-labeled neurons are small (<300 mm 2 in area), 41.2% are medium (300-600 mm 2 in area), and 34.5% are large (>600 mm 2 in area) (Figure 2(b) ). To further confirm the subpopulation distribution of K 2P 1.1 in DRG, we also did the double labeling for K 2P 1.1 and distinct DRG neuronal markers. Approximately 45.8% (258/563) of K 2P 1.1-labeled neurons are positive for neurofilament-200 (NF200, a marker for medium/large diameter neurons and myelinated A-fibers) (Figure 3(a) ), 31.9% (158/495) for calcitonin gene-related peptide (CGRP, a marker for small/ medium peptidergic neurons) (Figure 3(b) ), and 18.9% (92/488) for isolectin B4 (IB4, a marker for small nonpeptidergic neurons) (Figure 3(c) ).
Downregulation of K 2P 1.1 in the injured DRG after SNL
We further examined whether peripheral nerve injury changed the expression of DRG K 2P 1.1. SNL, but not sham surgery, time-dependently decreased the levels of K 2P 1.1 mRNA and protein in the L 4 DRG on the ipsilateral side (Figure 4(a) and (b) ). The amount of K 2P 1.1 protein in the ipsilateral L 4 DRG was reduced by 53.8% on day 3 (P < 0.05), 58.3% on day 7 (P < 0.05), and 52.8% on day 14 (P < 0.05) post-SNL compared to sham surgery mice at the corresponding time point (Figure 4(a) ). No significant changes in the levels of K 2P 1.1 protein were seen in either contralateral L 4 DRG or ipsilateral intact L 3 DRG (Figure 4(c) ). Consistently, the ratios of ipsilateral side to contralateral side of K 2P 1.1 mRNA levels were decreased by 85.8% on day 3 (P < 0.05), 84.0% on day 7 (P < 0.05), and 79.2% on day 14 (P < 0.05) post-SNL compared to naive mice (Figure 4(b) ). We also quantified the number of K 2P 1.1-positive neurons in the contralateral and ipsilateral L 4 DRGs on day 7 post-SNL or sham surgery. SNL, but not sham surgery, reduced the number of K 2P 1.1-positive neurons by 56.6% in the ipsilateral L 4 DRG compared to that in the corresponding contralateral L 4 DRG (P < 0.05) (Figure 4(d) ). To further verify the effect of SNL on the expression of K 2P 1.1 in the injured DRG neurons, we examined K 2P 1.1 protein level in the ipsilateral L 4 DRG on day 7 after sciatic nerve axotomy or sham surgery. Like after SNL, the level of K 2P 1.1 protein in the ipsilateral L 4 DRG post-axotomy was reduced by 44.7% compared to that post-sham surgery (Figure 4(e) ).
Rescuing DRG K 2P 1.1 reduction blocked neuropathic pain development
Is the reduced K 2P 1.1 in the injured DRG involved in neuropathic genesis? To address this question, we examined the effect of overexpressing K 2P 1.1 in the injured DRG through microinjection of AAV-DJ expressing full-length K 2P 1.1 mRNA (AAV-K 2P 1.1) into the ipsilateral L 4 DRG to rescue SNL-induced downregulation of K 2P 1.1. AAV-DJ expressing EGFP (AAV-EGFP) was used as a control. Like AAV5 reported previously, [13] [14] [15] [16] 18 AAV-DJ requires three to four weeks to become expressed and its expression lasts for at least six weeks ( Figure 5 ). EGFP-labeled AAV-DJ was limited to the ipsilateral L 4 DRG neurons and their fibers and terminals four weeks after microinjection ( Figure 5 were labeled by EGFP ( Figure 5(e) ). EGFP fluorescence was detected in many nerve fibers and terminals innervating the dorsal horn ipsilateral to the microinjection ( Figure 5(g) and (h) ). No cell bodies of spinal cord neurons were labeled. Consistent with previous reports, [13] [14] [15] [16] 18 the injected DRG, stained with hematoxylin and eosin, retained its structural integrity and contained no visible leukocytes (data not shown).
To examine the effect of AAV-K 2P 1.1 microinjection into the injured DRG on SNL-induced development of pain hypersensitivity, we carried out the SNL model or sham surgery four weeks after viral microinjection. As expected, the level of K 2P 1.1 protein was significantly decreased in the ipsilateral L 4 DRG on day 7 post-SNL from the SNL plus PBS or AAV-EGFP group compared to the naive group (Figure 6(a) ). This decrease was completely rescued in the SNL plus AAV-K 2P 1.1 group (Figure 6(a) ). In the sham plus AAV-K 2P 1.1 group, the amount of K 2P 1.1 protein in the injected DRG markedly increased by 2.27-fold compared to the naive group (Figure 6(a) ). Consistent with previous studies, 13, 15, 18, [22] [23] [24] SNL led to mechanical, thermal, and cold pain hypersensitivities on the ipsilateral side from day 3 to 7 after SNL in the PBS-or AAV-EGFP-injected group. The paw withdrawal frequencies in response to mechanical stimuli applied to the ipsilateral hind paw were significantly increased as compared with preinjury baseline values, a behavioral indication of mechanical pain hypersensitivity (Figure 6(b) and (c) ). The paw withdrawal latencies of the ipsilateral hind paw in response to thermal and cold were markedly less than those at baseline, an indication of thermal and cold pain hypersensitivities, respectively (Figure 6(d) and (e) ). Microinjection of AAV-K 2P 1.1 did not alter basal paw withdrawal responses to mechanical, thermal, or cold stimuli on the ipsilateral hid paw of sham group (Figure 6(b) to (e)), but microinjection of AAV-K 2P 1.1 abolished SNL-induced pain hypersensitivities (Figure 6(b) to (e)). Compared with the baseline level, there were no significant increases in paw withdrawal frequencies in response to mechanical stimuli and no marked decreases in paw withdrawal latency in response to thermal or cold stimulation on the ipsilateral side from the AAV-K 2P 1.1 plus SNL group (Figure 6(b) to (e)). As expected, microinjection of neither PBS nor virus altered basal paw withdrawal responses on the contralateral side ( Figure 6 (f) to (h)).
Rescuing DRG K 2P 1.1 reduction attenuated neuropathic pain maintenance
We also investigated the role of DRG K 2P 1.1 in the maintenance of neuropathic pain. We subjected mice to SNL two weeks after DRG viral microinjection. Mechanical, thermal, and cold pain hypersensitivities were completely developed in both the AAV-EGFPand AAV-K 2P 1.1-injected groups on day 7 post-SNL (Figure 7(a) to (d) ). These pain hypersensitivities were significantly attenuated on days 14, 21, and 28 after SNL in the AAV-K 2P 1.1-injected group, but not in the AAV-EGFP-injected group (Figure 7(a) to (d) ). Microinjection of neither AAV-K 2P 1.1 nor AAV-EGFP altered paw withdrawal frequency or latency on the contralateral side (Figure 7 (e) to (g)).
Overexpressing K 2P 1.1 in the DRG did not affect locomotor functions
We finally determined whether overexpressing K 2P 1.1 in the injured DRG influenced locomotor function of experimental animals. As shown in Table 1 , microinjection of AAV-K 2P 1.1, AAV-EGFP, and PBS did not produce any effects on locomotor functions including placing, grasping, and righting reflexes among the treated groups. Convulsions and hypermobility were not observed in any of the injected animals. In addition, we did not observe any significant difference in general behaviors, including the gait and spontaneous activity, between the PBS-and virus-injected groups.
Discussion
Four major findings arose from the present study. First, K 2P 1.1 was highly expressed in the DRG and distributed in small-, medium-, and large-sized DRG neurons. Second, K 2P 1.1 channel was significantly downregulated in the injured DRG during both the development and maintenance periods of SNL-induced pain hypersensitivities. Third, rescuing this downregulation by overexpressing K 2P 1.1 mRNA in the injured DRG blocked the development and maintenance of SNLinduced neuropathic pain. Finally, overexpressing DRG K 2P 1.1 did not affect acute pain and locomotor functions. These findings suggest that the DRG K 2P 1.1 channel may be a novel potential target for preventing and treating neuropathic pain. K 2P 1.1 mRNA is abundant in peripheral and central nerve systems of rodents and human beings. 25, 26 In mouse forebrain, K 2P 1.1 was highly expressed in astrocyte and contributed to its passive conductance. 27 In contrast, in mouse and rat DRG, the data from present study and the previous work 12 showed that K 2P 1.1 was expressed exclusively in the neurons, but not in the satellite glial cells. These findings indicate that the cell-type expression pattern of K 2P 1.1 may have tissuerelated specificity. We further observed that, in addition to medium-and large-sized DRG neurons reported previously, 12 K 2P 1.1 channel was also distributed in small-sized DRG neurons. The discrepancy in DRG subpopulation distribution pattern between the present study and previous work 12 is unknown, but may be related to the differences in the use of primary antibodies.
Total 15 members of the K 2P channel family have been identified. 5, 6 The expression of several members of this family has been found to be downregulated in the DRG under pathological pain conditions. DRG expression of TASK1, TASK2, TASK3, and TRESK mRNAs was decreased in the first four days after Complete Freund's Adjuvant-induced inflammation and their decrease was associated with inflammation-evoked spontaneous pain behavior. 28 The expression of TRESK transcript, but not TEEK1, TREK2, TASK1, and TRAAK transcripts, in the injured DRG was diminished three weeks after axotomizing sciatic nerve. 29 Injured DRG displayed a significant reduction in the level of K 2P 1.1 mRNA one, two, and four weeks following spared nerve injury and in the level of TASK3 mRNA only one week following spared nerve injury. 12 Any knowledge of the changes in the expression of DRG K 2P channels in the development of neuropathic pain (i.e., within one week after peripheral nerve injury) is still lacking. The present study demonstrated a marked downregulation of K 2p 1.1 mRNA and protein in the injured DRG 3, 7, and 14 days after SNL. Given that SNL-induced pain hypersensitivities appears on day 3, reaches a peak on day 7, and lasts for at least 14 days post-SNL, 18, 30 our finding strongly suggests that SNLinduced downregulation of K 2P 1.1 expression in the injured DRG is associated with the development and maintenance of SNL-induced neuropathic pain. How SNL led to DRG K 2P 1.1 downregulation is still unclear, but this downregulation might be caused by epigenetic modifications (e.g., DNA methylation and histone modification) and/or the decrease in RNA stability. Our recent work showed that the expression of one DNA methyltransferase, DNMT3a, was increased in the injured DRG neurons and that this increase was essential for the silencing of DRG K 2P 1.1 under chemotherapyinduced neuropathic pain conditions (data not shown). Whether DNMT3a contributes to SNL-induced DRG K 2P 1.1 downregulation remains to be determined.
We provided what we believe to be the first evidence that K 2P 1.1 downregulation in the injured DRG contributes to neuropathic pain development and maintenance. Extensive studies have revealed that K 2P channels are responsible for the regulation of resting membrane potential and cellular excitability. 7, 8 Under physiological conditions, K 2P generates hyperpolarizing leak currents that stabilize cells below firing threshold. 7, 8 As K 2P 1.1 exhibits an inwardly rectifying profile in heterologous expression system, 11 K 2P 1.1 is thought to be important in setting the resting membrane potential of cells. Interestingly, we found that overexpressing K 2P 1.1 in the DRG neurons did not affect acute pain. This no effect may be attributed to the fact that DRG neuronal excitability is dependent on the expression and function of sodium channels, calcium channels, and potassium channels. Our recent work demonstrated that DRG K 2P 1.1 knockdown in naive mice did not alter action potential threshold although this knockdown depolarized resting membrane potential (data not shown). Thus, without any changes in the expression and function of other channels under normal conditions, the hyperdepolarization of the resting membrane potential produced alone by DRG overexpressing K 2P 1.1 might not be enough to affect action potential as well as acute pain induced by acute noxious stimulation.
However, SNL-induced DRG K 2P 1.1 downregulation observed in the present study is likely involved in the formation of abnormal ectopic discharges in the injured DRG and consequent initiation and expression of SNL-induced pain hypersensitivities. Our recent work revealed that DRG K 2P 1.1 knockdown depolarized resting membrane potential, decreased current threshold for the activation in the action potentials, and increased the number of action potentials in small, medium, and large DRG neurons and led to neuropathic pain-like symptoms (data not shown). It is very likely that SNLinduced K 2P 1.1 downregulation in the DRG neurons renders those neurons more prone to hyperexcitability. The increase in excitability of small, medium, and large DRG neurons may drive the release of the neurotransmitters and/or neuromodulators from their primary afferent terminals and lead to spinal central sensitization. 1, 3, 31, 32 The latter contributes to the development and maintenance of neuropathic pain. 1, 3, 31, 32 This conclusion is strongly supported by our behavioral observations that rescuing K 2P 1.1 downregulation in the injured DRG through microinjection of AAV-K 2P 1.1 into the ipsilateral L 4 DRG attenuated the development and maintenance of SNL-induced pain hypersensitivities. Therefore, nerve injury-induced DRG K 2P 1.1 downregulation likely participates in the mechanisms underlying neuropathic pain induction and maintenance. In summary, we have identified the expression and distribution of K 2P 1.1 in DRG neurons and revealed its time-dependent downregulation in the injured DRG following peripheral nerve injury. Given that restoring the downregulation of K 2P 1.1 in the injured DRG neurons alleviated pain hypersensitivities in both the development and maintenance of SNL-induced neuropathic pain, without altering acute pain and motor function, K 2P 1.1 may be a target for the management of this disorder. Nevertheless, it is worth noting that K 2P 1.1 is also expressed in other body tissues. Targeting K 2P 1.1 may have potential off-target effects that remains to be further investigated. 
